Literature summary for 5.4.2.11 extracted from

Evans, M.J.; Morris, G.M.; Wu, J.; Olson, A.J.; Sorensen, E.J.; Cravatt, B.F.
Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides (2007), Mol. Biosyst., 3, 495-506.

Search for more literature for 5.4.2.11

Crystallization (Commentary)

Crystallization (Comment)	Organism
modeling study of enzyme in complex with inhibitor 1-benzyl 4-[(3R,4R,6R)-6-[1-(hex-5-ynoyloxy)-1-methylethyl]-1-oxaspiro[2.5]oct-4-yl] (2R)-2-(2,3-dihydro-1H-indol-3-ylmethyl)butanedioate	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
K100A	no covalent modification by inhibitor 1-benzyl 4-[(3R,4R,6R)-6-[1-(hex-5-ynoyloxy)-1-methylethyl]-1-oxaspiro[2.5]oct-4-yl] (2R)-2-(2,3-dihydro-1H-indol-3-ylmethyl)butanedioate	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
1-benzyl 4-[(3R,4R,6R)-6-[1-(hex-5-ynoyloxy)-1-methylethyl]-1-oxaspiro[2.5]oct-4-yl] (2R)-2-(2,3-dihydro-1H-indol-3-ylmethyl)butanedioate	i.e. MJE3, spiroepoxide with anti-proliferative effects in human breast cancer cells. MJE3 covalently inactiviates enzyme at K100	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	P18669	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)